Cost-utility and expected value of perfect information related to trabectedin in the treatment of metastatic soft-tissue sarcoma: the publicly funded comments explored Ideally, survival times should be reported as exhaustive means together with Kaplan-Meier curves based on a large-enough randomized clinical trial, as this would enable an unbiased analysis of hazard ratios-the time-to-event summary statistic of choice [4] . However, most trials provide median survivals when all patients have not met the end points and the valid estimation of means based on the censored data could result in statistical modelling/estimation. While it is possible to carry out CEAs and indirect comparisons (ICs), including meta-analyses based on mean time-to-event data [5] , medians are not a suitable basis for IC [4] or CEA.
